Market Update (NYSE:ACT): Actavis And Perrigo Receive FDA Approval Of Guaifenesin/Pseudoephedrine, The Store Brand Equivalent To Mucinex® D Tablets

[PR Newswire] – TASE) announced today that Actavis has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application (ANDA) for guaifenesin/pseudoephedrine tablets and that Perrigo will begin shipments in . . . → Read More: Market Update (NYSE:ACT): Actavis And Perrigo Receive FDA Approval Of Guaifenesin/Pseudoephedrine, The Store Brand Equivalent To Mucinex® D Tablets Similar Articles: Company Update: Actavis plc (NYSE:ACT) – Actavis cannot drop old version of Alzheimer’s drug – appeals court Stock Update (NYSE:ACT): Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30 Company Update (NYSE:ACT): (OFFICIAL)-UPDATE 1-Actavis’ superbug antibiotic gets U.S. approval (Feb. 25)